Erratum to hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients
Erratum to: Transl Androl Urol 2021;10:3199-207
In the article that appeared on Page: 3199-3207, Vol 10, No 7 (July 2021) Issue of the Translational Andrology and Urology (TAU) (1), there was an error in the Footnote.
The name of the series reported in the Conflicts of Interest should be “Current and Future Topics on Prostate Cancer”, instead of “Management of Advanced Genitourinary Malignancies”.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Lyou Y, Dorff TB. Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients. Transl Androl Urol 2021;10:3199-207. [Crossref] [PubMed]
